ORPHELIA Pharma, a French company specialized in the development and commercialization of pediatric medicines, today announced that initiative Octalfa joined the company as a minority shareholder, director and operating partner.
Continue readingTargeOn SAS to become ORPHELIA Pharma SA
TargeOn SAS, a French company specialized in the development and commercialization of pediatric medicines, today announced that the company will be renamed ORPHELIA Pharma SA, effective October 9th, 2015.
Continue readingORPHELIA Pharma at Bio-Europe, Munich – Germany
ORPHELIA Pharma will be present in Munich on November, 2 to 4 for the 21st annual BIO-Europe Congress. This event is the Europe’s largest partnering conference serving the global biotechnology industry. Do not hesitate to contact us to meet at this occasion.
More info at: http://www.ebdgroup.com/bioeurope/index.php and http://www.partneringone.com
Visit us at: http://www.orphelia-pharma.eu
ORPHELIA Pharma at RARE 2015, Montpellier – France
ORPHELIA Pharma will be present in Montpellier on November 26th and 27th for the RARE congress. This event brings together manufacturers, researchers, clinicians, patient organizations, regulatory authorities, and investors involved in the field of rare diseases. Do not hesitate to contact us to meet at this occasion.
More info at: http://www.rare2015.com
Visit us at: http://www.orphelia-pharma.eu
ORPHELIA Pharma at CPhI, Madrid – Spain
ORPHELIA Pharma will be present in Madrid on October 13th and 14th, 2015, in the number one Pharma event that brings together most international pharmaceuticals companies. Do not hesitate to contact us to meet at this occasion.
More info at: http://www.cphi.com/europe/home
Visit us at: http://www.orphelia-pharma.eu